Imbed Biosciences
PrivateLast Round
Strategic
Feb 3, 2026
Est. Valuation
$15.7M
Total Funding Raised
$35.49M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Imbed Biosciences operates in Healthcare & Life Sciences and is based in Middleton, Wisconsin. Its latest recorded funding round was a Strategic round in February 2026.
Imbed Biosciences is a medical device company that develops advanced synthetic therapies and antimicrobial wound matrices for the treatment of surgical wounds, burns, chronic ulcers, and soft-tissue repair.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imbed Biosciences Comparables
Compare Imbed Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Engineered Tissue Solutions | 86% | |
| Gel4Med | 85% | |
| Bravida Medical | 84% |
For institutional investors. Book with your work email.
Imbed Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 3, 2026 | ||||
| Convertible Debt | Jan 8, 2024 | ||||
| Debt | Dec 14, 2023 | ||||
| Debt | May 17, 2023 | ||||
| Series B | Nov 11, 2021 | ||||
Grant | Oct 14, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Imbed Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | Grant |
| NIH RADx | Grant |
| Wisconsin Economic Development Corporation | Grant |
| WISC Partners | Seed, Series A |
| Formidable Asset Management | Series A |
| Center for Technology Commercialization | Grant |
| National Institutes of Health (NIH) | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 93% MoM.
- Apr 1, 2026
Company has commercial products sold in the U.S. and overseas.
For institutional investors. Book with your work email.
Imbed Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Imbed Biosciences's valuation, stock price, and market status.
Is Imbed Biosciences a public or private company?
Imbed Biosciences is a private company.
What is the current stock price of Imbed Biosciences?
Imbed Biosciences is a private company, so its shares have no public market price. Caplight tracks Imbed Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Imbed Biosciences worth (valuation)?
Imbed Biosciences's valuation is estimated at $15.7M based on funding round data.
Can I buy Imbed Biosciences stock?
Imbed Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Imbed Biosciences's last funding round?
Imbed Biosciences's most recent funding round was Strategic on February 3, 2026.
Who are the main investors in Imbed Biosciences?
Key investors in Imbed Biosciences include National Institute of Arthritis and Musculoskeletal and Skin Diseases, WISC Partners, Formidable Asset Management.
Will Imbed Biosciences IPO soon?
No public IPO plans have been announced for Imbed Biosciences.
How can I track Imbed Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Imbed Biosciences's shares on secondary markets.